Peginterferon alfa-2a (40KD) (PEGASYSĘ) in combination with ribavirin (RBV): efficacy and safety results from a phase III, randomized, double-blind, multicentre study examining effect of duration of treatment and RBV dose
Background
Study Aims
Study Design (1)
Study Design (2)
Primary Endpoint
Main Inclusion Criteria
Main Exclusion Criteria
Patient Characteristics
Results: SVR Genotype 1
Results: SVR Genotype 1 Low Viral Titre
Results: SVR Genotype 1 High Viral Titre
Results: SVR Genotype Non-1
Sustained Virologic Response: Effect of Cirrhosis
Rate of Withdrawal From Treatment
Ribavirin Discontinuations for Adverse Events / Lab Abnormalities
Serious Adverse Events
Summary (1)
Summary (2)
Summary (3)
Study Countries
Home Page: http://www.natap.org
Download presentation source